GHA
JAZZ icon

GW Henssler & Associates’s Jazz Pharmaceuticals JAZZ Stock Holding History

GW Henssler & Associates’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,725
Closed -$214K – 242
2023
Q2 		$214K Sell
1,725
-185
-10% -$24.9K 0.01% 197
2023
Q1 		$279K Sell
1,910
-22
-1% -$3.25K 0.02% 179
2022
Q4 		$308K Hold
1,932
– – 0.02% 157
2022
Q3 		$258K Sell
1,932
-70
-3% -$10.6K 0.02% 166
2022
Q2 		$312K Sell
2,002
-1,201
-37% -$185K 0.02% 142
2022
Q1 		$499K Buy
3,203
+47
+1% +$6.82K 0.03% 121
2021
Q4 		$402K Buy
+3,156
New +$415K 0.03% 164
2021
Q3 		– Sell
-2,831
Closed -$503K – 168
2021
Q2 		$503K Sell
2,831
-1
-0% -$173 0.03% 126
2021
Q1 		$465K Hold
2,832
– – 0.03% 133
2020
Q4 		$467K Buy
2,832
+18
+0.6% +$2.68K 0.04% 124
2020
Q3 		$401K Buy
2,814
+185
+7% +$22.9K 0.03% 125
2020
Q2 		$290K Buy
2,629
+37
+1% +$4.09K 0.03% 138
2020
Q1 		$259K Sell
2,592
-504
-16% -$65.2K 0.03% 166
2019
Q4 		$462K Buy
3,096
+396
+15% +$53.9K 0.04% 142
2019
Q3 		$346K Hold
2,700
– – 0.03% 150
2019
Q2 		$385K Buy
+2,700
New +$363K 0.03% 151

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

GW Henssler & Associates's JAZZ Position: Q3 2023 in Review

GW Henssler & Associates sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2023, closing a stake of 1,725 shares — an estimated $214K sold.

GW Henssler & Associates first reported a position in JAZZ in Q2 2019 and held it in 16 quarters. The position peaked at $503K in Q2 2021. 484 funds tracked by Wall St. Rank hold JAZZ as of Q3 2023.

  • GW Henssler & Associates reported no remaining Jazz Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • GW Henssler & Associates sold 1,725 Jazz Pharmaceuticals shares in Q3 2023, an estimated $214K.
  • GW Henssler & Associates first reported a position in Jazz Pharmaceuticals in Q2 2019 and held it in 16 quarters.
  • GW Henssler & Associates's Jazz Pharmaceuticals position peaked at $503K in Q2 2021.
  • 484 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2023.

Based on GW Henssler & Associates's 13F filing for Q3 2023, filed 24 Oct 2023.